Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I still contend that if the SC accepts Amarin's case it will be to address the appeals court's abuse of rule 36. Best case, the case gets remanded for an en banc hearing.
If the trial for primary and first secondary endpoint lasts 90 days I don't think we'll see the results until the end of the year unless the trial is stopped early.
Enrollment hasn't even started but assume the first subjects are enrolled this month, it will take several months to enroll that many patients. I think 3 months to enroll the total number is not unrealistic meaning the last patient would be enrolled sometime in July. October end date means we probably won't see any data until November/December.
Didn't see that as I only skimmed it. So, I guess so. But they can stop testing at any time if there is proof of efficacy.
Agreed. It's a 90 day test though so we won't know the results for a while. I just skimmed the info so didn't see the start date. Do you know when that is?
The info regarding aviptadil is on page 40 for anyone reading the file. Thanks for posting this.
Study: 1 in 4 hospitalized patients with most severe form of COVID-19 will die
About 23% of people hospitalized with COVID-19 experience the most severe form of the disease and roughly one in four of them will die due to its complications, according to a study published Friday by PLOS ONE.
An additional 60% suffer from the "normal" symptoms, but still have serious heart and lung complications that carry a 10% risk for death, the data showed.
Collectively, COVID-19 patients in these two categories are more than seven times as likely to be hospitalized due to the illness and nearly three times as likely to die from it, compared to the 17% percent of patients with mild infections, the researchers said
https://www.upi.com/Health_News/2021/04/02/coronavirus-patient-subgroups-disease-severity-study/3491617386548/?ur3=1
Even the executive summary of the article you published earlier only said Javitt had requested excluding data from some sites due to icu's being over capacity at those sites. To me that sounds like a reasonable request as it would be difficult under those circumstances to properly conduct a trial. As has been mentioned several times the FDA will have the final say and so we will have to wait on their decision.
More fud. The article isn't accessible without a subscription so there's no way to know what's in it.
You missed the part where Russia is rolling large convoys of tanks and armaments towards the Ukraine border, this after Biden stated clearly that we stand with Ukraine. They're laughing at us.
Interesting that Hikma insists the case has been closed for a year with an appeal pending before the Supreme Court.
Standing seems to be the opt out for courts to dismiss cases after watching all the election cases be dismissed under that legal reasoning. What standing do we have here other than as interested shareholders not a party to this case?
Appropriate since Amarin has seemingly been in zugzwang forever.
Just don't eat it please. The inevitable video would definitely go viral.
The stock or the investors?
The only reason the SC might take this case is to review the abuse of the use of rule 36 to dispose of cases. I doubt seriously it would be reviewed on the merits of our case but only as a way to rebuke the appeals court's laziness. But honestly, from our perspective it's still a win if they kick it back to the CAFC for further review.
Misleading header on your post. That's good info however on potential ema approval though. However, it won't occur until the FDA approves zyesami.
Makes sense and with the float here it could take forever for the shorts to exit. SMH
Given today's reaction and the fact that it wasn't that long ago we were above .50 a share on no news I think investors believe vaccines have solved the covid problem. Given some of the statistics regarding the efficacy of the vaccines they're right, at least in the near term. We may be too late to the party.
Looks like we're headed steadily down into the close. It's possible that at the close we're only up 3 or 4 cents on the day. What a disappointment.
It's being walked back down which indicates this was clearly a buy the rumor sell the news event. Hopefully the trend will reverse later today.
Expected. They are Neurorx's partner and it was a neurorx conference call, not a rlftf call. Brpa also has a tiny float. Much easier to drive the price higher.
Is that available on otc stocks?
It won't go to a dollar on this news. An EUA will be required. Enjoy today, the news is great.
You'll know where we're headed before the teleconference. Check the Swiss exchange and expect a press release to precede the call.
By that I take it to mean prospects for you getting any sleep are not good?
Former President Trump's exit from the White House coincided with a slump in ratings for cable news channels and digital news sites, according to a Washington Post analysis.
Data from media tracking firm ComScore as well as the Nielsen company indicated drops in traffic across websites for the Post, which lost roughly one-fourth of its monthly web traffic, as well as The New York Times, which lost roughly 17 percent of its traffic over January and February.
In the cable news ratings wars, CNN lost nearly 50 percent of its prime-time audience over the first few months of 2021, according to the Post, while MSNBC lost more than a fourth and Fox News lost just 6 percent, causing CNN to lose its briefly-won ratings dominance for the month of January.
That's a possibility but not a certainty. I have seen that happen to stocks which had a reverse split to remain listed because their share price was drifting below a dollar. They were already in financial trouble before the split and remained so after the split. Since they can't obtain reasonable financing for ongoing operations and are not cash flow positive they rely on dilution for financing. Aurora cannabis is a perfect example of this. That doesn't mean it's a fait accompli for all stocks that have a reverse split.
Holdings aren't necessarily diluted in a reverse split. Your total monetary holdings don't change immediately. If you own 1000 shares at 1 dollar each and a 10 for 1 reverse split occurs you will hold 100 shares at 10 dollars apiece. Trading after the split will determine whether or not the company made the right decision to conduct a reverse split.
The point of that post was a reverse split, not the CEO. It's pretty much a given that there will be a reverse split in order to get the share price high enough for a nasdaq listing. I think it's pretty far down the road though. There's so much more to obtaining a listing than just share price.
Because major brokerage firms can't buy stock on the pink sheets?
Their previous conference call was rushed because of a board resignation if you'll recall. It was damage control.
Not necessarily. They could remand the case to the appeals court based solely on excessive use of rule 36. The SC could take the case for the purpose of instructing the appeals court to stop abusing the process.
Amarin set the table for their failure by picking that venue.
That would be like bringing up a pitcher from double A to start the World Series game 7.
Can we repeal liability shields for the vaccine makers?
Well there's your problem right there! Everyone knows only heartless republicans watch Sean. They got no beat.
I looked into the company and as near as I can tell none of their products have gone through the FDA approval process. Is that correct?
Either the site isn't reddy to roll yet or the info has been doctored
Ok, thanks. Scrip numbers should improve and by quite a bit I think. The first quarter is traditionally slower. I'm looking forward to scrip numbers going over 100,000 and staying there week to week.